KaydedilenlerDerginizi ekleyin

Dergiler / Aurum Journal of Health Sciences / 2020 / Cilt: 2 - Sayı: 2

BCG Vaccine and New Tuberculosis Vaccines Against Mycobacterium tuberculosis: A review

Özgül KISA
Sayfa
141–153
Yayın Tarihi
2020-05-31
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This review explains the recapitulation of the current status of new TB vaccines updated with scientific literature references.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Mycobacterium tuberculosis (M. tuberculosis) causes tuberculosis (TB) which is a serious infectious disease.
📊
Temel Bulgular & Veri:Bacteria are spread from person to person through tiny droplets released into the air via sneezing and coughing.
💡
Sonuç & Katkı:This review explains the recapitulation of the current status of new TB vaccines updated with scientific literature references.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Mycobacterium tuberculosis · new vaccines · clinical studies

Abstract

Mycobacterium tuberculosis (M. tuberculosis) causes tuberculosis (TB) which is a serious infectious disease. Bacteria are spread from person to person through tiny droplets released into the air via sneezing and coughing. Despite global efforts to control TB, the disease is the second most common cause of death after Acquired Immune Deficiency Syndrome (AIDS). Currently, Bacillus Calmette-Guérin (BCG) vaccine is used to prevent tuberculous meningitis and miliary disease, particularly in young children, but its protective efficacy is variable in adults. Therefore, there is an urgent need for the development of alternative TB vaccines. Recently, new TB vaccine development efforts have been advanced in different clinical studies. Most of these vaccines are live-attenuated or recombinant mycobacterium, live viral vector-based, and protein/adjuvant vaccines. This review explains the recapitulation of the current status of new TB vaccines updated with scientific literature references.

🔖

Bu Makaleye Atıf Yap

KISA, Ö. (2020). BCG Vaccine and New Tuberculosis Vaccines Against Mycobacterium tuberculosis: A review. Aurum Journal of Health Sciences, Cilt: 2 - Sayı: 2, 141–153. https://ajindex.com/articles/825983

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (6)

  1. Arbues, A., Aguilo, J. I., Gonzalo-Asensio, J., Marinova, D., Uranga, S., Puentes, E., Fernandez, C., Parra, A., Cardona, P. J., Vilaplana, C., Ausina, V., Williams, A., Clark, S., Malaga, W., Guilhot, C., Gicquel, B., Martin, C. (2013). Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis based vaccine to enter clinical trials. Vaccine, 31(42), 4867–4873. Doi: 10.1016/j.vaccine.2013.07.051. Baldwin, S. L., Bertholet, S., Reese, V. A., Ching, L. K., Reed, S. G., Coler, R. N. (2012). The importance of adjuvant formulation in the development of a tuberculosis vaccine. The Journal of Immunology, 188(5), 2189-2197. Doi: 10.4049/jimmunol.1102696. Barry, K., Ming, W., Yan, G., Johanna, G., Kamalakannan, P., Lewis, V., Schrager, K. (2016). Novel approaches to preclinical research and TB vaccine development. Tuberculosis, 99, 12-15. https://doi.org/10.1016/j.tube.2016.05.012
  2. Cardona, P. J. (2006). RUTI: A new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis, 86, 273–289. https://doi.org/10.1016/j.tube.2006.01.024.
  3. Clark, S., Lanni, F., Marinova, D., Rayner, E., Martin, C., Williams, A. (2017). Revaccination of Guinea pigs with the live attenuated Mycobacterium tuberculosis vaccine MTBVAC improves BCG’s protection against tuberculosis. Journal Infectious Disease, 216(5), 525-533. https://doi.org/10.1093/infdis/jix030
  4. Daniel, T. M. (2006). The history of tuberculosis. Respiratory Medicine, 100(11), 1862-1870. http://dx.doi.org/10.1016/j.rmed.2006.08.006
  5. Dockrell, H. M. (2016). Towards new TB vaccines: what are the challenges? Pathogens Disease, 74, 1-7. Doi: 10.1093/femspd/ftw016 Frick, M. (2015). The tuberculosis vaccines pipeline: a new path to the same destination? In: Pipeline report HIV, hepatitis C virus and tuberculosis drugs, diagnostics, vaccines, preventive technologies towards a cure and immune-based and gene therapies in development. Anderea, B., (eds.). HIV i-Base/Treatment action group. 163-178.
  6. Gopal, R., Khader, S. A. (2013). Vaccines against tuberculosis: moving forward with new concepts. Expert Review of Vaccines, 12(8), 829-831. Doi:10.1586/14760584.2013.814836. Gupta, A., Ahmad, F. J., Ahmad, F., Gupta, U. D., Natarajan, M., Katoch, V. M., Bhaskar, S. (2012). Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in Guinea pig model. Vaccine, 30(43), 6198-6209. Doi: 10.1016/j.vaccine.2012.07.061. Haw